Dark

Check out our Dark Pool Levels

CYTO
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)
stock NASDAQ

Inactive

Dec 19, 2024

0.3000USD-25.944%(-0.1051)829,919

Pre-market

0.00USD-100.000%(-0.41)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 21, 2022

09:04AM EST Altamira Therapeutics Reports Approval Of Bentrio Nasal Spray In Malaysia Benzinga

Jan 13, 2022

11:48AM EST Altamira Therapeutics Provides Update On RNA Therapeutics Program Benzinga

Dec 16, 2021

09:13AM EST Altamira Therapeutics Announces Randomization Of First Patients In Bentrio Trial In House Dust Mite Allergy Benzinga

Dec 1, 2021

09:10AM EST Altamira Therapeutics Announces Randomization Of First Patient In Bentrio Trial In Seasonal Allergic Rhinitis Benzinga

Oct 14, 2021

08:01AM EDT Altamira Therapeutics Receives FDA Acceptance For Bentrio 510(k) Application Benzinga

Sep 27, 2021

07:49AM EDT Altamira Therapeutics Provides Update On Bentrio Program; Says 510(k) Premarket Notification For Allergy Indication Submitted to FDA, Distributors Signed Up For Two Southeast Asian Countries Benzinga

Sep 21, 2021

08:11AM EDT Altamira Therapeutics To Provide Business Update On Bentrio Program Sept. 27 Benzinga

Sep 8, 2021

08:37AM EDT Altamira Therapeutics 1H EPS $(0.54) Benzinga

Aug 6, 2021

09:01AM EDT Altamira Therapeutics Reports Effects Of Bentrio Nasal Spray Against Influenza A Virus; Says Showed 'Significant reduction of viral titer in human nasal epithelium model both in prevention and treatment of influenza infection ' Benzinga

Share